• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病中谷氨酸能神经支配的区域特异性丧失。

Region-specific loss of glutamate innervation in Alzheimer's disease.

作者信息

Hardy J, Cowburn R, Barton A, Reynolds G, Lofdahl E, O'Carroll A M, Wester P, Winblad B

出版信息

Neurosci Lett. 1987 Jan 2;73(1):77-80. doi: 10.1016/0304-3940(87)90034-6.

DOI:10.1016/0304-3940(87)90034-6
PMID:2882446
Abstract

Synaptosomal D-aspartate has been used as a marker for glutamate neurons in control and in postmortem Alzheimer's disease brains. This technique shows a marked (60%) decrease of the glutamate uptake site in cortical and hippocampal regions. There were no significant changes in subcortical regions. We interpret these results as indicating loss of, or damage to, cortical glutamatergic innervation. These losses probably represent the biochemical correlate of pyramidal neuron damage in Alzheimer's disease.

摘要

突触体D-天冬氨酸已被用作对照和死后阿尔茨海默病大脑中谷氨酸能神经元的标志物。该技术显示皮质和海马区域中谷氨酸摄取位点显著减少(60%)。皮质下区域没有明显变化。我们将这些结果解释为表明皮质谷氨酸能神经支配的丧失或损伤。这些损失可能代表了阿尔茨海默病中锥体神经元损伤的生化关联。

相似文献

1
Region-specific loss of glutamate innervation in Alzheimer's disease.阿尔茨海默病中谷氨酸能神经支配的区域特异性丧失。
Neurosci Lett. 1987 Jan 2;73(1):77-80. doi: 10.1016/0304-3940(87)90034-6.
2
Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease.阿尔茨海默病中突触前和突触后谷氨酸能功能的区域分布
Brain Res. 1988 Jun 14;452(1-2):403-7. doi: 10.1016/0006-8993(88)90048-0.
3
A postmortem study of amino acid neurotransmitters in Alzheimer's disease.阿尔茨海默病中氨基酸神经递质的尸检研究。
Ann Neurol. 1986 Nov;20(5):616-21. doi: 10.1002/ana.410200510.
4
Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex.
J Neurochem. 1995 May;64(5):2193-202. doi: 10.1046/j.1471-4159.1995.64052193.x.
5
Dementia of the Alzheimer's type: changes in hippocampal L-[3H]glutamate binding.
J Neurochem. 1987 Feb;48(2):543-51. doi: 10.1111/j.1471-4159.1987.tb04127.x.
6
Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type.阿尔茨海默型老年痴呆症中皮质谷氨酸能结合位点的差异性改变。
Proc Natl Acad Sci U S A. 1990 Feb;87(4):1352-6. doi: 10.1073/pnas.87.4.1352.
7
Glutamatergic denervation in Alzheimer's disease--a cautionary note.阿尔茨海默病中的谷氨酸能去神经支配——一则警示
J Neurol Neurosurg Psychiatry. 1987 Jun;50(6):825. doi: 10.1136/jnnp.50.6.825.
8
Regional distribution of amino acid transmitters in postmortem brains of presenile and senile dementia of Alzheimer type.早老性和老年性阿尔茨海默型痴呆症尸检大脑中氨基酸递质的区域分布。
Ann Neurol. 1986 Mar;19(3):263-9. doi: 10.1002/ana.410190307.
9
Release of aspartate and glutamate caused by chloride reduction in synaptosomal incubation media.
J Neurochem. 1984 Mar;42(3):875-7. doi: 10.1111/j.1471-4159.1984.tb02763.x.
10
Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease.生前脑氨基酸浓度表明阿尔茨海默病中富含谷氨酸的神经元发生选择性退化。
Neuroscience. 1990;38(3):571-7. doi: 10.1016/0306-4522(90)90051-5.

引用本文的文献

1
miR-361-5p contributes to the pathogenesis of Alzheimer's disease.微小RNA-361-5p促成阿尔茨海默病的发病机制。
Sci Rep. 2025 Aug 23;15(1):31046. doi: 10.1038/s41598-025-17112-z.
2
Fueling Brain Inhibition: Integrating GABAergic Neurotransmission and Energy Metabolism.为大脑抑制提供能量:整合γ-氨基丁酸能神经传递与能量代谢
Neurochem Res. 2025 Apr 7;50(2):136. doi: 10.1007/s11064-025-04384-0.
3
Gray matter gamma-hydroxy-butyric acid and glutamate reflect beta-amyloid burden at old age.灰质中的γ-羟基丁酸和谷氨酸反映了老年时的β-淀粉样蛋白负荷。
Alzheimers Dement (Amst). 2024 Apr 30;16(2):e12587. doi: 10.1002/dad2.12587. eCollection 2024 Apr-Jun.
4
The glutamatergic system in Alzheimer's disease: a systematic review with meta-analysis.阿尔茨海默病中的谷氨酸能系统:系统评价与荟萃分析。
Mol Psychiatry. 2024 Jul;29(7):2261-2273. doi: 10.1038/s41380-024-02473-0. Epub 2024 Feb 16.
5
Vesicular Glutamate Transporter Changes in the Cortical Default Mode Network During the Clinical and Pathological Progression of Alzheimer's Disease.在阿尔茨海默病的临床和病理进展过程中,皮质默认模式网络中的囊泡谷氨酸转运体变化。
J Alzheimers Dis. 2023;94(1):227-246. doi: 10.3233/JAD-221063.
6
Alzheimer's disease as a synaptopathy: Evidence for dysfunction of synapses during disease progression.阿尔茨海默病作为一种突触病:疾病进展过程中突触功能障碍的证据。
Front Synaptic Neurosci. 2023 Mar 9;15:1129036. doi: 10.3389/fnsyn.2023.1129036. eCollection 2023.
7
Altered gene expression in excitatory neurons is associated with Alzheimer's disease and its higher incidence in women.兴奋性神经元中基因表达的改变与阿尔茨海默病及其在女性中较高的发病率有关。
Alzheimers Dement (N Y). 2023 Feb 8;9(1):e12373. doi: 10.1002/trc2.12373. eCollection 2023 Jan-Mar.
8
Asymmetric dysregulation of glutamate dynamics across the synaptic cleft in a mouse model of Alzheimer's disease.阿尔茨海默病小鼠模型中突触裂隙谷氨酸动力学的不对称失调。
Acta Neuropathol Commun. 2023 Feb 14;11(1):27. doi: 10.1186/s40478-023-01524-x.
9
EAAT2 as a therapeutic research target in Alzheimer's disease: A systematic review.EAAT2作为阿尔茨海默病的治疗研究靶点:一项系统综述。
Front Neurosci. 2022 Aug 10;16:952096. doi: 10.3389/fnins.2022.952096. eCollection 2022.
10
Triiodothyronine Treatment reverses Depression-Like Behavior in a triple-transgenic animal model of Alzheimer's Disease.三碘甲状腺原氨酸治疗可逆转阿尔茨海默病三联转基因动物模型中的类抑郁行为。
Metab Brain Dis. 2022 Dec;37(8):2735-2750. doi: 10.1007/s11011-022-01055-9. Epub 2022 Aug 11.